Search Results
Mar 25, 2026, 18:06 ET Royce Global Trust (NYSE: RGT) as of Feb 28, 2026
View original content:https://www.prnewswire.com/news-releases/royce-global-trust-nyse-rgt-as-of-feb-28-2026-302725448.htmlSOURCE Royce
More news about: Royce Global Trust
Feb 27, 2026, 13:55 ET Royce Global Trust (NYSE: RGT) as of Jan 31, 2026
View original content:https://www.prnewswire.com/news-releases/royce-global-trust-nyse-rgt-as-of-jan-31-2026-302699874.htmlSOURCE Royce
More news about: Royce Global Trust
Jan 26, 2026, 16:00 ET Royce Global Trust (NYSE: RGT) as of Dec 31, 2025
View original content:https://www.prnewswire.com/news-releases/royce-global-trust-nyse-rgt-as-of-dec-31-2025-302670384.htmlSOURCE Royce
More news about: Royce Global Value Trust
Dec 23, 2025, 12:31 ET Royce Global Trust (NYSE: RGT) as of Nov 30, 2025
View original content:https://www.prnewswire.com/news-releases/royce-global-trust-nyse-rgt-as-of-nov-30-2025-302648868.htmlSOURCE Royce
More news about: Royce Global Trust
Dec 01, 2025, 14:14 ET Royce Global Trust, Inc. (NYSE-RGT) declares Year-end Common Stock Distribution of $0.19 Per Share
NEW YORK, Dec. 1, 2025 /PRNewswire/ -- Royce Global Trust, Inc. (NYSE-RGT) (the "Fund") has declared an annual distribution of $0.19 per share on its Common Stock. The distribution, optionally payable in additional shares
More news about: Royce Global Value Trust
Nov 24, 2025, 14:47 ET Royce Global Trust (NYSE: RGT) as of Oct 31, 2025
View original content:https://www.prnewswire.com/news-releases/royce-global-trust-nyse-rgt-as-of-oct-31-2025-302624888.htmlSOURCE Royce
More news about: Royce Global Value Trust
Oct 27, 2025, 13:52 ET Royce Global Trust (NYSE: RGT) as of Sep 30, 2025
View original content:https://www.prnewswire.com/news-releases/royce-global-trust-nyse-rgt-as-of-sep-30-2025-302595632.html
More news about: Royce Global Value Trust
Sep 25, 2025, 13:22 ET Royce Global Trust (NYSE: RGT) as of Aug 31, 2025
View original content:https://www.prnewswire.com/news-releases/royce-global-trust-nyse-rgt-as-of-aug-31-2025-302567447.html SOURCE Royce
More news about: Royce Global Value Trust
Sep 05, 2025, 05:00 ET GLP-1 Agonists Market to Show Impressive Growth at a CAGR of 10.8% During the Forecast Period (2025-2034) | DelveInsight
GLP-1 agonists in the clinical trial pipeline include Orforglipron, Survodutide, Retatrutide, Tirzepatide, Semaglutide, AMG-133, VK-2735, RGT-075, RG 6640/CT-388, and others.Discover which indication is expected to grab the major GLP-1 agonists market share @
More news about: DelveInsight Business Research, LLP
Sep 02, 2025, 14:46 ET Royce Global Trust (NYSE: RGT) as of Jul 31, 2025
View original content:https://www.prnewswire.com/news-releases/royce-global-trust-nyse-rgt-as-of-jul-31-2025-302544187.html SOURCE Royce
More news about: Royce Global Value Trust, Inc.
Aug 27, 2025, 17:30 ET Argent is Growing Through M&A: Projected Merged Company Value of $100M in AC8 Asset Acquisition
SYDNEY, Aug. 27, 2025 /PRNewswire/ -- Argent BioPharma Ltd (ASX: RGT) has signed a binding term sheet to acquire the core assets and IP of AusCann Group Holdings Ltd (AC8). The acquisition includes the Neuvis®
More news about: Argent BioPharma Ltd.
Jul 30, 2025, 16:01 ET Royce Global Trust (NYSE: RGT) as of Jun 30, 2025
View original content:https://www.prnewswire.com/news-releases/royce-global-trust-nyse-rgt-as-of-jun-30-2025-302517837.html SOURCE Royce
More news about: Royce Global Value Trust
Jun 26, 2025, 13:49 ET Royce Global Trust (NYSE: RGT) as of May 31, 2025
View original content:https://www.prnewswire.com/news-releases/royce-global-trust-nyse-rgt-as-of-may-31-2025-302492630.html SOURCE Royce
More news about: Royce Global Trust
Jun 13, 2025, 09:00 ET Regor to Present Data on its Lead Obesity Candidate, RGT-075, at the 85th Scientific Sessions of American Diabetes Association (ADA)
placebo-controlled study to evaluate multiple doses of RGT-075 over 36 weeks in adults with obesity or overweight with weight-related comorbidities. The trial has enrolled approximately 240 participants. All participants on RGT-075 will be given RGT-075 once daily (QD) titrated up over 12 weeks. The primary
More news about: Regor Therapeutics
Jun 03, 2025, 15:50 ET Royce Global Trust (NYSE: RGT) as of Apr 30, 2025
View original content:https://www.prnewswire.com/news-releases/royce-global-trust-nyse-rgt-as-of-apr-30-2025-302472424.html SOURCE Royce
More news about: Royce Global Trust
May 14, 2025, 09:30 ET Rgenta Therapeutics Announces Presentation of Preclinical Data from Lead Program, RGT-61159, a Potent and Selective Small Molecule Inhibitor of MYB RNA, at the European Hematology Association (EHA) 2025 Congress
Saturday, June 14 (18:30 - 19:30 CEST)Abstract #: PS1424 About RGT-61159RGT-61159 is an orally available small molecule designed to specifically modulate splicing of the transcription factor MYB resulting in the inhibition
More news about: Rgenta Therapeutics
Apr 25, 2025, 13:00 ET Rgenta Therapeutics Presents Preclinical Data on RGT-61159, a Potent, Selective Oral Small Molecule Inhibitor of MYB, Demonstrating Robust Anti-Tumor Activity in Several Monotherapy Models of AML and Synergistic Activity when Combined with Standard of Care for AML
demonstrated the robust anti-tumor activity of tolerated doses of RGT-61159 and synergistic activity both in vitro and in vivo when administered in combination with agents used in AML standard of care. About RGT-61159RGT-61159 is an orally available small molecule designed to
More news about: Rgenta Therapeutics
Apr 24, 2025, 14:24 ET Royce Global Trust (NYSE: RGT) as of Mar 31, 2025
View original content:https://www.prnewswire.com/news-releases/royce-global-trust-nyse-rgt-as-of-mar-31-2025-302437694.html SOURCE Royce
More news about: Royce Global Trust
Apr 23, 2025, 19:00 ET Argent BioPharma Enters Germany - Europe's Largest Market
Australia, April 23, 2025 /PRNewswire/ -- Argent BioPharma Ltd. (ASX: RGT) (OTCQB: RGTLF), a clinical-stage biopharmaceutical company specializing in neuroimmune therapies, is pleased to announce its official entry into the
More news about: Argent BioPharma Ltd.